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Spheres of Influence
Trial and Error: Should Pregnant Women Be
Research Subjects?
Scientists, policy makers, bioethicists, and
the public are currently split on an issue that
cuts to the heart of scientific research and
draws into the purportedly objective, ratio-
nal world of science people's passionate
views on personal autonomy: whether feder-
al research guidelines that bar pregnant
women, and in effect their fetuses, from
clinical trials protect or discriminate against
women.
The federal government is preparing to
respond to growing pressure to change pro-
tectionist laws and give women greater con-
trol over their own health. In March 1994,
the Institute ofMedicine (IOM), a division
ofthe National Academy ofSciences, issued
a report urging current law to be changed. If
adopted by the federal government, the
IOM's recommendations would clear the
way for a pregnant woman to participate in
medical drug experiments, for conditions
related or unrelated to pregnancy, even
when the safety of her fetus cannot be
assured.
New medical treatments are rarely tested
on pregnant women for safety and efficacy,
including drugs such as analgesics, psychoac-
tive agents, antimicromobials, diuretics, and
cough medicines reportedly used by three
out offour pregnant consumers. Excluding a
woman from clinical trials based on her
pregnant status could be deemed discrimina-
tory by denying her the benefits ofscientific
discovery. In addition, pregnant women
offer a fertile area for research on environ-
mentally mediated diseases, many ofwhich
affect the reproductive system in particular
or cause abnormalities in children ofparents
exposed to environmental toxins.
Experimentation on pregnant women
can produce unexpected results because of
the numerous physiological changes during
pregnancy that alter the body's disposition
ofdrugs. According to IOM, these physio-
logical changes include increased plasmavol-
ume, bodyweight and bodyfat, metabolism,
and hormone levels that can decrease the
concentration ofa drug in the body and its
therapeutic effects. Moreover, reliance on
reporting ofadverse effects byclinicians does
not provide sufficient data to assess the safe-
ty and effectiveness of drugs for pregnant
women. "The basic presumption is that a
woman who may become pregnant can get
information about an agent and can make
an informed decision," said Anthony
Schialli, a reproductive toxicologist and
director of the residency program at
Georgetown University Medical Center.
"But information for a new drug she takes
consists of interpreting animal data . . .
which is the same as the risks for environ-
mental agents . . ." One scientist involved in
the IOM report stated, "Our approach was
driven by the fact that there are not enough
proven safe treatments for pregnant women
who become ill during pregnancy or even
before with diabetes, hypertension, a cold,
an allergy, or preterm labor."
The 16-member panel of the IOM
unanimously supported the participation of
pregnant women in research studies as a
right and urged that studies include rather
than exclude them. The bottom line in
IOM's resolution boils down to the issue of
informed consent. The IOM committee said
a pregnant woman, like any research subject,
must be given complete disclosure of the
risks and benefits to which she may be
exposing herself and her unborn baby,
preferably byherhealth care provider.
Among the panel's recommendations are
thefollowing:
* Even when evidence is unknown or
ambiguous, the decision about accept-
ability of risk to the pregnancy or off-
spring should be made by the woman as
part ofthe informed consent process;
* Pregnancy, contraception, and termina-
tion options should be discussed as part
ofthe consent process in clinical studies
that pose unknown or unforeseeable
risks to the unborn child;
* Where risk ofsignificant harm to a preg-
nant woman or her fetus is known or
can be plausibly inferred, investigators
and the IOM Institutional Review Board
(IRB) should have the final say;
* NIH should advance clinical research for
the management of three categories of
medical conditions that may threaten
the successful course of pregnancy: pre-
existing (e.g., lupus); during (e.g., gesta-
tional diabetes); and those that affect
pregnancyoutcome (resulting in preterm
labor, forexample).
"This report, in its insistence on respect-
ing the rights of the person, goes further
than the research community had agreed
on," said Daniel Federman, co-chair of the
IOM panel and dean of medical education
at Harvard Medical School. However,
Federman admitted that a major bone of
contention within the committee and more
broadly the scientific and public policy
communities was the issue of setting limits
on a pregnant woman's role in clinical trials
when there is no prospect ofmedical benefit
to her and a risk of significant harm to
potential offspring.
"Some of the committee worried that
[the restriction] leaves an opening through
which [the IRB] can justify a diminution of
her autonomy. We took that concern seri-
ously but as a group were not unanimous
for giving absolute autonomy to the preg-
nant person," Federman said. No such
restrictions exist for her male counterpart,
although the IOM report noted that scien-
tists have long suspected that offspring may
be at risk because ofexposure of the father
as well. These risks include spontaneous
abortion, stillbirth, impaired growth, and
structural and functional abnormalities as a
result of environmental and other expo-
sures.
For example, at recent congressional
hearings on Persian Gulfsyndrome, several
men testified that their exposure to chemi-
cal warfare or other agents had adverse
effects on their offspring. Yet, according to
Vivian Pinn, director ofthe NIH's Office of
Research on Women's Health, which con-
tracted the IOM study, male-mediated toxi-
city in medical experimentation is deprecat-
ed. "Not as much attention is paid to the
possible effects ofthe male on the fetus, and
yet the sperm goes with the ova ... and we
should know exactly what effect it has,"
Pinn said.
The IOM report noted that bringing
pregnant women into clinical studies poses
new complications, dangers, and a sticky
dilemma: by including pregnant women in
clinical trials, fetuses are exposed to the risk
ofteratogenicity; by excluding them the sci-
entific community and public lack hard
facts on how various drugs or environmen-
tal toxins affect a pregnant woman and her
fetus.
At the NIEHS, where many studies
focus on reproductive toxicity, there is no
consensus about the ideal way to gather
these facts. During a recent exchange, some
NIEHS scientists argued that existing feder-
al rules against experimenting on pregnant
women are beneficial to protect a fetus and
preventexploitation.
Alan Wilcox, chiefofthe NIEHS's epi-
demiology branch, whose landmark epi-
demiological studies have examined the
effects of diethylstilbestrol on the offspring
ofwomen who took the drug during preg-
nancy, is, like many scientists, ambivalent.
While there is "no prospect of the NIEHS
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[testing environmental toxins on pregnant
women], and the issue has not yet come
before the institute," Wilcox said, the case
for involving pregnant women in clinical tri-
als ofuntested medications is persuasive.
Protectionists part company with the
IOM panel on the issue of a woman's per-
sonal autonomy. "If not paternalistic, then
what is exclusion?" asked Ruth Macklin, a
professor of epidemiology and social medi-
cine at Albert Einstein College ofMedicine
in New York. "Why should some distant
scientist whose relationship lasts a brieftime
make the ultimate determination rather than
a woman who presumably cares more about
her unborn child?"
Current law classifies pregnant women
as vulnerable subjects worthy ofspecial pro-
tection, along with fetuses, prisoners, the
mentally disabled, and children, who may
only occasionally participate in trials. But
the IOM report views this distinction as
"suggesting that pregnant women are less
autonomous or more easily exploited than
other persons-an inference that the com-
mittee has found no evidence to support."
Curtis L. Meinert, director ofthe Center for
Clinical Trials at the Johns Hopkins
University School of Hygiene and Public
Health, agrees with the report and questions
the special status of pregnant women.
Meinert would not rule out recruiting preg-
nant research subjects.
Federal agencies such as the National
Institutes ofHealth and the Food and Drug
Administration are deciding whether to
revamp protectionist regulations implement-
ed in the 1970s to enable women of child-
bearing age, fetuses, and children to partici-
pate in drug experiments and research stud-
ies that could have benefits for both them
and society. Ifapproved by the federal gov-
ernment, the amended regulations could
require investigators to include a pregnant
woman in their studies to test a new therapy
unless her exclusion could be justified. But
there mayalso beless radical options.
William Dommel, chair of the Public
Health Service's Human Subject Regulation
Drafting Committee, said that the commit-
tee is reviewing events that led up to the
rules' enactment beginning with the
Nuremberg trials. According to Dommel,
more recent milestones such as the IOM
report, FDA's revised guidelines on research
involving women, and the NIH Revital-
izationAct of1993 will also be reviewed.
The regulations pertaining to research,
development, and related activities involving
fetuses, pregnant women, and human in
vitro fertilization "have not been reviewed
for more than 15 years," said Dommel, who
indicated that the drafting committee's work
is dependent, in part, on the NIH Human
Embryo Panel's recommendations. "We are
... looking at what, if any, changes are
needed with respect to research involving
testing on these populations, and the NIH
panel will make its recommendations and
complete their work before we begin work-
ing on actual changes," he added.
The FDA's Center for Drug Evaulation
will meet sometime this fall to "look at these
issues around pregnant women and clinical
trials . . . " according to Ruth Merkatz, spe-
cial assistant on women's health issues to
FDA Commissioner David Kessler. The
agenda will include "collecting information
on the use of drugs and other products in
pregnancy, under what circumstances trials
could and would be done, and how data is
collected on women [as research subjects] in
pregnancy," Merkatz said.
Meanwhile, the Office of Research on
Women's Health is on the fence. The NIH
inclusion guidelines charge ORWH with
ensuring that all women of childbearing
years arewell represented in research studies,
including clinical trials, for diseases that
affect them. ORWH officials also serve on
the groups reviewing DHHS regulations to
examine all issues relating to including preg-
nant women in clinical studies. "We need
the information, but obtaining it can have
great risks to both mother and child ... and
all issues must be considered-both imme-
diate and longterm," said ORWH Assistant
Director Judith LaRosa. "Participating in a
clinical trial may be a mother's choice, but
at what point does a fetus have a say in the
matter?"
Lionel B. Edwards, formerly assistant
vice president of international clinical
research at Hoffman-LaRoche, contends
that few women will "spontaneously volun-
teer themselves or their offspring unless they
are dying, so the majority oftrials won't get
enoughwomen to participate anyway."
Karen H. Rothenberg, director of law
and health care programs at the University
of Maryland School of Law, restates the
question that confounds attempts to resolve
this issue: "Do you then say, okay, as a class,
women are excluded or as a class they are
entitled to be included?" Rothenberg points
to a landmark Supreme Court decision, the
Johnson Controls case, which upheld a
woman's right, rather than her employer's,
to decide whether or not to expose her fetus
to workplace environmental hazards and
preempt tort claims brought by children
allegedly injured by their mothers' exposure
as evidence supporting a woman's right to
decide to participate.
Ellen Wright Clayton, an assistant pro-
fessor ofpediatrics and assistant professor of
law at Vanderbilt University, thinks it
unlikely that children injured before birth
due to their parent's participation in
typically occurs in the research setting, there
will rarely be any basis for successful lawsuits
by children or particularly by parents."
However, Clayton argues that proposals to
limit or ban drug manufacturers' liability for
injuries "seems unjust" and argues that the
potential costs of liability should be borne
by manufacturers as the costs ofseeing that
new products are fully tested before they are
brought to market.
Environmental law specialists Ellen
Flannery and Sanford Greenberg with the
law firm of Covington and Burling in
Washington, DC, think companies have
more to worry about by excluding pregnant
women from trials. They claim women who
are harmed by a commercial product would
have less grounds to sue manufacturers who
included them in clinical trials than those
who left them out. Rothenberg contends
that the manufacturers of diethylstilbestrol
lost because they had not done their home-
work. "Litigation did not result from clinical
trials, except at the University of Chicago
where there was a lack ofinformed consent
about the drug's risks," Rothenberg said. "If
they had looked at the data and done ade-
quate trials, [the companies] may never have
marketed [diethylstilbestrol]."
Edwards, former chair ofspecial popula-
tions for the Pharmaceutical Manufacturers
Association, said the industry sees the
changing rules as a "social readjustment"
and is "happy to go along with the consen-
sus," but cautions, "If excluding pregnant
women [means] according to the regulations
you could have a grant withheld or with-
drawn, that's another story. Don't subgroup
us to death or we'll never get a drug out the
door."
Merkatz thinks pregant women should
not be summarily dismissed from research if
the probable risk is clearly explained and
their participation can further scientific
knowledge. In a July 1993 article that
appeared in the New EnglandJournal of
Medicine, she points to substantial ethical
and legal precedent: "Ethical principles
articulated in the Belmont report-respect
for persons, beneficience and justice-as
well as recent actions by the Congress and
decisions by the U.S. Supreme Court sug-
gest that women should have the right to
make their own risk-benefit choices about
theirpregnancies."
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research would have grounds to sue.
"Looked at simply from the perspectives of
legal doctrine and extensive disclosure that
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